At week 16 , patients with JIA-American College of Rheumatology ( ACR ) 30 improvement entered the 24-week , double-blind part 2 after randomisation 1:1 to placebo or tocilizumab ( stratified by methotrexate and steroid background therapy ) for evaluation of the primary end point : JIA flare , compared with week 16 .